Septerna (NASDAQ:SEPN) Reaches New 52-Week Low – Here’s What Happened

Septerna, Inc. (NASDAQ:SEPN) shares hit a new 52-week low on Tuesday . The stock traded as low as $15.10 and last traded at $15.45, with a volume of 215 shares trading hands. The stock had previously closed at $15.61.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Cantor Fitzgerald initiated coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 target price for the company. TD Cowen started coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued a “buy” rating for the company. JPMorgan Chase & Co. initiated coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price on the stock. Finally, Wells Fargo & Company assumed coverage on Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 price target for the company.

Septerna Stock Down 1.0 %

The company has a 50-day moving average price of $21.14.

Institutional Investors Weigh In On Septerna

Several hedge funds and other institutional investors have recently modified their holdings of the stock. New York State Common Retirement Fund bought a new stake in Septerna in the 4th quarter valued at $32,000. SG Americas Securities LLC acquired a new stake in Septerna during the fourth quarter worth about $185,000. Rhumbline Advisers bought a new position in Septerna during the fourth quarter valued at about $458,000. Finally, Bank of New York Mellon Corp acquired a new position in Septerna in the 4th quarter valued at approximately $872,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.